Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Digitization has allowed Sanofi to optimize manufacturing and automate document preparation. And now, the firm predicts that ...

Sanofi’s commitment to sustainability has been recognized globally, with TIME ranking it as the world’s 10th most sustainable company across all industries and #1 in pharma and biotech. This accolade ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.

(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) ...